We’re all about humanity
We make a difference in the lives of patients around the world with serious and rare diseases because the vitality of our science is powered by our core values.
A global commitment
Our commitment to patients has no borders. In addition to our global corporate headquarters in Bridgewater, NJ, we have offices throughout Europe and in Japan, with more than 600 employees who are dedicated to serving the needs of patients and their families. We continue to build our global infrastructure and organizational capabilities as we pursue regulatory approvals in multiple regions.
Our company has evolved significantly over the years, but our commitment to patients remains. As we look toward the future, we are inspired by our vision to deliver life-altering therapies to small patient populations experiencing big health problems.
Our key milestones
Insmed’s first product is approved and launches in Japan. Insmed reports positive Phase 1 data for its earlier-stage product candidate in healthy volunteers.
Insmed’s first product is approved in Europe; initial country launches begin
Insmed reports positive data for its Phase 2 product candidate and announces plans to advance to Phase 3 development.
Insmed opens its new, state-of-the-art global headquarters in Bridgewater, NJ, to support the Company’s continued growth.
Insmed opens an office in Tokyo, expanding its global presence to Japan.
Insmed is granted accelerated approval by the FDA for its first therapy.
Insmed submits a New Drug Application to the FDA for its lead product candidate.
Insmed opens an office in Utrecht, Netherlands, further expanding its presence to Europe.
Insmed enters into a worldwide license agreement with AstraZeneca for a product candidate, expanding the company’s rare disease pipeline.
Insmed receives Orphan Drug Designation, Qualified Infectious Disease Product designation, and Fast Track status for its lead product candidate.
Insmed enters into a business combination with Transave, acquiring its late-stage candidate. The new company maintains the name Insmed.
Transave pioneers the early development of an inhaled liposomal antibiotic, an advancement that will later enable the approval of the Company’s first therapy.
Insmed is incorporated in the Commonwealth of Virginia and becomes a public company (INSM) after acquiring Celtrix Pharmaceuticals in a reverse merger.
Transave is founded as a private company by Dr. Frank Pilkiewicz in Monmouth Junction, NJ, to develop inhaled pharmaceuticals for the treatment of lung diseases.
Insmed is founded as a private company by Dr. Joseph Larner in Charlottesville, Va., to develop medicines to treat diabetes.
An installation at Insmed’s global headquarters honors the Company’s past as we look toward the future. From the early days of the two original companies that formed Insmed to the FDA approval and launch of our first therapy, the wall highlights some of the most significant moments in Insmed’s history and showcases the values that we live every day.